Minority Health and Health Equity Archive

Permanent URI for this communityhttp://hdl.handle.net/1903/22236

Browse

Filters

2005 - 20072

Settings

Author: search.filters.author.Kahn, JonathanSubject: search.filters.subject.Pharmacotherapy

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Race in a Bottle
    (2007) Kahn, Jonathan
    Two years ago, on June 23, 2005, the U.S. Food and Drug Administration approved the first “ethnic” drug. Called BiDil (pronounced “bye-dill”), it was intended to treat congestive heart failure—the progressive weakening of the heart muscle to the point where it can no longer pump blood efficiently —in African-Americans only. The approval was widely declared to be a significant step toward a new era of personalized medicine, an era in which pharmaceuticals would be specifically designed to work with an individual’s particular genetic makeup. Known as pharmacogenomics, this approach to drug development promises to reduce the cost and increase the safety and efficacy of new therapies. BiDil was also hailed as a means to improve the health of African-Americans, a community woefully underserved by the U.S. medical establishment. Organizations such as the Association of Black Cardiologists and the Congressional Black Caucus strongly supported the drug’s approval. A close inspection of BiDil’s history, however, shows that the drug is ethnic in name only.
  • Thumbnail Image
    Item
    BiDil: Race Medicine Or Race Marketing?
    (2005) Sankar, Pamela; Kahn, Jonathan
    Recent Food and Drug Administration (FDA) approval of the first drug with a race-specific indication has fueled the controversy over the meaning of race and ethnicity and raised questions over whether this move should be seen as an advance or a setback in the struggle to address disparities in health status associated with race. The drug, BiDil, combines two generics long recognized as benefiting patients with heart failure, irrespective of race or ethnicity. The push to bring these drugs to market as a race-specific treatment was motivated by the peculiarities of U.S. patent law and a willingness to exploit race to gain commercial and regulatory advantage.